# Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

> **NCT03161756** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Melanoma and Skin Cancer Trials Limited** · enrollment: 72 (estimated)

## Conditions studied

- Melanoma Stage Iv
- Melanoma Stage Iii
- Melanoma

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03161756
- **Lead sponsor:** Melanoma and Skin Cancer Trials Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-07
- **Primary completion:** 2021-12-31
- **Final completion:** 2023-12
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2022-04-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161756, "Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03161756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*